166 related articles for article (PubMed ID: 33672789)
21. Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.
Probst BL; McCauley L; Trevino I; Wigley WC; Ferguson DA
PLoS One; 2015; 10(8):e0135257. PubMed ID: 26301506
[TBL] [Abstract][Full Text] [Related]
22. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
[TBL] [Abstract][Full Text] [Related]
23. Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.
Romero R; Sayin VI; Davidson SM; Bauer MR; Singh SX; LeBoeuf SE; Karakousi TR; Ellis DC; Bhutkar A; Sánchez-Rivera FJ; Subbaraj L; Martinez B; Bronson RT; Prigge JR; Schmidt EE; Thomas CJ; Goparaju C; Davies A; Dolgalev I; Heguy A; Allaj V; Poirier JT; Moreira AL; Rudin CM; Pass HI; Vander Heiden MG; Jacks T; Papagiannakopoulos T
Nat Med; 2017 Nov; 23(11):1362-1368. PubMed ID: 28967920
[TBL] [Abstract][Full Text] [Related]
24. UHRF1 regulation of the Keap1-Nrf2 pathway in pancreatic cancer contributes to oncogenesis.
Abu-Alainin W; Gana T; Liloglou T; Olayanju A; Barrera LN; Ferguson R; Campbell F; Andrews T; Goldring C; Kitteringham N; Park BK; Nedjadi T; Schmid MC; Slupsky JR; Greenhalf W; Neoptolemos JP; Costello E
J Pathol; 2016 Feb; 238(3):423-33. PubMed ID: 26497117
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2-mutant lung cancer.
Cai MC; Chen M; Ma P; Wu J; Lu H; Zhang S; Liu J; Zhao X; Zhuang G; Yu Z; Fu Y
Int J Cancer; 2019 Feb; 144(4):788-801. PubMed ID: 30411339
[TBL] [Abstract][Full Text] [Related]
27. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells.
Liang C; Shi S; Liu M; Qin Y; Meng Q; Hua J; Ji S; Zhang Y; Yang J; Xu J; Ni Q; Li M; Yu X
Cancer Res; 2019 Jan; 79(1):133-145. PubMed ID: 30355620
[TBL] [Abstract][Full Text] [Related]
28. Esculetin induces antiproliferative and apoptotic response in pancreatic cancer cells by directly binding to KEAP1.
Arora R; Sawney S; Saini V; Steffi C; Tiwari M; Saluja D
Mol Cancer; 2016 Oct; 15(1):64. PubMed ID: 27756327
[TBL] [Abstract][Full Text] [Related]
29. A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy.
Zhang D; Hou Z; Aldrich KE; Lockwood L; Odom AL; Liby KT
Mol Cancer Ther; 2021 Sep; 20(9):1692-1701. PubMed ID: 34158350
[TBL] [Abstract][Full Text] [Related]
30. KEAP1/NRF2 axis regulates H
He J; Zhang X; Lian C; Wu J; Fang Y; Ye X
Gene; 2019 Apr; 691():8-17. PubMed ID: 30594636
[TBL] [Abstract][Full Text] [Related]
31. Microenvironmental Activation of Nrf2 Restricts the Progression of Nrf2-Activated Malignant Tumors.
Hayashi M; Kuga A; Suzuki M; Panda H; Kitamura H; Motohashi H; Yamamoto M
Cancer Res; 2020 Aug; 80(16):3331-3344. PubMed ID: 32636316
[TBL] [Abstract][Full Text] [Related]
32. Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-essential Amino Acids.
LeBoeuf SE; Wu WL; Karakousi TR; Karadal B; Jackson SR; Davidson SM; Wong KK; Koralov SB; Sayin VI; Papagiannakopoulos T
Cell Metab; 2020 Feb; 31(2):339-350.e4. PubMed ID: 31813821
[TBL] [Abstract][Full Text] [Related]
33. NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes.
Singh A; Daemen A; Nickles D; Jeon SM; Foreman O; Sudini K; Gnad F; Lajoie S; Gour N; Mitzner W; Chatterjee S; Choi EJ; Ravishankar B; Rappaport A; Patil N; McCleland M; Johnson L; Acquaah-Mensah G; Gabrielson E; Biswal S; Hatzivassiliou G
Clin Cancer Res; 2021 Feb; 27(3):877-888. PubMed ID: 33077574
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.
Emadi A; Jun SA; Tsukamoto T; Fathi AT; Minden MD; Dang CV
Exp Hematol; 2014 Apr; 42(4):247-51. PubMed ID: 24333121
[TBL] [Abstract][Full Text] [Related]
35. Effects of deficiency of Kelch-like ECH-associated protein 1 on skeletal organization: a mechanism for diminished nuclear factor of activated T cells cytoplasmic 1 during osteoclastogenesis.
Sakai E; Morita M; Ohuchi M; Kido MA; Fukuma Y; Nishishita K; Okamoto K; Itoh K; Yamamoto M; Tsukuba T
FASEB J; 2017 Sep; 31(9):4011-4022. PubMed ID: 28515152
[TBL] [Abstract][Full Text] [Related]
36. Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation.
Gong M; Li Y; Ye X; Zhang L; Wang Z; Xu X; Shen Y; Zheng C
Cell Commun Signal; 2020 Jun; 18(1):98. PubMed ID: 32576270
[TBL] [Abstract][Full Text] [Related]
37. KRAS G12D mutation eliminates reactive oxygen species through the Nrf2/CSE/H
Fan K; Zhang S; Ni X; Shen S; Wang J; Sun W; Suo T; Liu H; Ni X; Liu H
Acta Biochim Biophys Sin (Shanghai); 2022 Nov; 54(11):1731-1739. PubMed ID: 36514219
[TBL] [Abstract][Full Text] [Related]
38. Effect of lysine to alanine mutations on the phosphate activation and BPTES inhibition of glutaminase.
McDonald CJ; Acheff E; Kennedy R; Taylor L; Curthoys NP
Neurochem Int; 2015 Sep; 88():10-4. PubMed ID: 25510640
[TBL] [Abstract][Full Text] [Related]
39. MBD1 is an Epigenetic Regulator of KEAP1 in Pancreatic Cancer.
Zhang B; Xu J; Li C; Shi S; Ji S; Xu W; Liu J; Jin K; Liang D; Liang C; Liu L; Liu C; Qin Y; Yu X
Curr Mol Med; 2016; 16(4):404-11. PubMed ID: 26980696
[TBL] [Abstract][Full Text] [Related]
40. Regulation of CD137 expression through K-Ras signaling in pancreatic cancer cells.
Glorieux C; Huang P
Cancer Commun (Lond); 2019 Jul; 39(1):41. PubMed ID: 31288851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
